Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C19H18N4O2 |
| Molecular Weight | 334.3718 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C2=NC3=C(N2)C=CC(=C3)C4=NNC(=O)CC4C
InChI
InChIKey=GLBJJMFZWDBELO-UHFFFAOYSA-N
InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
| Molecular Formula | C19H18N4O2 |
| Molecular Weight | 334.3718 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1660359
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1660359
Pimobendan (INN, or pimobendane; tradenames Vetmedin, Acardi, and Heartmedin) is a veterinary medication. Under the trade name Acardi, it is available for human use in Japan. Usually, this medicine is used to treat acute heart failure and chronic heart failure (mild to moderate in severity). By increasing the calcium ion sensitivity to protein regulating myocardial contraction and also by inhibiting phosphodiesterase (PDE-III) activity, this medicine dilates the blood vessels and improves the symptoms of heart failure such as shortness of breath and difficulty in breathing. Pimobendan is metabolized into an active metabolite (desmethylpimobendan) by the liver. The parent compound, pimobendan, is a potent calcium sensitizer while desmethylpimobendan is a more potent phosphodiesterase III inhibitor. Pimobendan is 90–95% bound to plasma proteins in circulation. This may have implications in patients suffering from low blood protein levels (hypoproteinemia/hypoalbuminemia) and in patients that are on concurrent therapies that are also highly protein bound.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The novel insulinotropic mechanism of pimobendan: direct enhancement of the exocytotic process of insulin secretory granules by increased Ca2+ sensitivity in beta-cells. | 1998 Mar |
|
| Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. | 1999 Apr |
|
| Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes. | 2000 Jan |
|
| Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium. | 2001 Feb |
|
| Mechanism of action of Ca2+ sensitizers--update 2001. | 2001 Sep |
|
| Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy. | 2002 Dec |
|
| A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. | 2002 May-Jun |
|
| Mechanisms of action of novel cardiotonic agents. | 2002 Sep |
|
| Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension. | 2003 Jul |
|
| Inhibition and facilitation by pimobendan, a calcium sensitizer, of catecholamine secretion from bovine adrenal chromaffin cells. | 2003 Mar |
|
| Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. | 2003 Mar |
|
| Investigation of pimobendan versus benazepril in canine myxomatous valvular disease. | 2003 Oct 4 |
|
| Selective blockade of nicotinic acetylcholine receptors by pimobendan, a drug for the treatment of heart failure: reduction of catecholamine secretion and synthesis in adrenal medullary cells. | 2005 Feb |
|
| [Cytokine antagonists and endothelin antagonists for therapy of heart failure]. | 2005 Feb 10 |
|
| Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers. | 2005 Jan |
|
| Preclinical dilated cardiomyopathy in the dobermann. | 2006 May 27 |
|
| Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. | 2007 |
|
| A pilot study to assess the feasibility of a submaximal exercise test to measure individual response to cardiac medication in dogs with acquired heart failure. | 2007 Aug |
|
| Translational medicine with a capital T, troponin T, that is. | 2007 Jul 20 |
|
| [Calcium sensitizer agents in heart failure therapy]. | 2007 May 28 |
|
| Treatment options in myocarditis: what we know from experimental data and how it translates to clinical trials. | 2007 Sep |
|
| Anaesthesia for the geriatric dog and cat. | 2008 Jun 1 |
|
| Validity, reliability, and responsiveness of the Kansas City Cardiomyopathy Questionnaire in anemic heart failure patients. | 2008 Mar |
|
| Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease". | 2008 Mar-Apr |
|
| Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded and randomized study". | 2008 Mar-Apr |
|
| Treatment of congestive heart failure in dogs. | 2008 Oct 25 |
|
| Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. | 2008 Sep-Oct |
|
| Chronic cor pulmonale secondary to pulmonary atherosclerosis in an African Grey parrot. | 2009 Apr 15 |
|
| Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease. | 2009 Mar-Apr |
|
| A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. | 2009 Oct |
|
| Sarcomere control mechanisms and the dynamics of the cardiac cycle. | 2010 |
|
| Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities. | 2010 Jan |
|
| Human cardiac tissue in a microperfusion chamber simulating extracorporeal circulation--ischemia and apoptosis studies. | 2010 Jan 18 |
Sample Use Guides
Acute heart failure: usually for adults, one capsule (2.5 mg of pimobendan) once daily
Chronic heart failure (mild to moderate in severity): usually for adults, one capsule (2.5 mg of pimobendan) twice daily after meals
Route of Administration:
Oral
composite platelet aggregation (area under the curve [AUC]) and maximal platelet aggregation (aggregation units [AUs]) at 10.0μM pimobendan were significantly decreased for collagen-induced aggregation (AUC, 349.7 ± 58.4 vs 285.1 ± 72.2; maximal platelet aggregation, 196.2 ± 25.8 AUs vs 161.5 ± 38.0 AUs), and the AUC and velocity of aggregation at 10.0μM pimobendan were significantly decreased for ADP-induced aggregation (AUC, 268.5 ± 35.1 vs 213.4 ± 77.2; velocity of aggregation, 15.7 ± 2.9 AUs/min vs 11.8 ± 3.5 AUs/min).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:12:48 GMT 2023
by
admin
on
Sat Dec 16 11:12:48 GMT 2023
|
| Record UNII |
9HTU209Z0N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9HTU209Z0N
Created by
admin on Sat Dec 16 11:12:48 GMT 2023 , Edited by admin on Sat Dec 16 11:12:48 GMT 2023
|
PRIMARY | |||
|
118428-37-8
Created by
admin on Sat Dec 16 11:12:48 GMT 2023 , Edited by admin on Sat Dec 16 11:12:48 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
